Table 1.
Baseline characteristics according to initiation of SGLT2i prescription after the first hospitalization for atherosclerotic cardiovascular disease
| Characteristic | All | SGLT2i treatment |
P value | |
|---|---|---|---|---|
| No | Yes | |||
| Number | 518,572 | 447,313 | 71,259 | |
| Age, yr | 68.7±12.1 | 69.8±11.8 | 61.6±11.7 | <0.001 |
| Male sex | 289,347 (55.8) | 244,192 (54.6) | 45,155 (63.4) | <0.001 |
| Time to initiation, mo | - | - | 10.6 (1.2–26.8) | |
| Urban residents | 212,152 (40.9) | 182,017 (40.7) | 30,135 (42.3) | <0.001 |
| Incomes (low 25%) | 152,749 (29.5) | 132,390 (29.6) | 20,359 (28.6) | <0.001 |
| Prescription | ||||
| Hospitals | - | - | 52,332 (73.4) | |
| Clinics | - | - | 18,497 (26.0) | |
| Etc. | - | - | 430 (0.6) | |
| Comorbidities | ||||
| Hypertension | 425,037 (82.0) | 367,326 (82.1) | 57,711 (81.0) | <0.001 |
| Dyslipidemia | 393,162 (75.8) | 330,498 (73.9) | 62,664 (87.9) | <0.001 |
| Antidiabetic drugsa | ||||
| Metformin | 360,462 (69.5) | 301,817 (67.5) | 58,645 (82.3) | <0.001 |
| DPP-4i | 235,352 (45.4) | 202,327 (45.2) | 33025 (46.4) | <0.001 |
| Insulin | 134,654 (26.0) | 121,148 (27.1) | 13,506 (19.0) | <0.001 |
| Sulfonylureas | 192,135 (37.1) | 160,143 (35.8) | 31,992 (44.9) | <0.001 |
| TZD | 30,799 (5.9) | 25,912 (5.8) | 4,887 (6.9) | <0.001 |
| AGI | 14,107 (2.7) | 12,545 (2.8) | 1,562 (2.2) | <0.001 |
| Meglitinide | 3,693 (0.7) | 3,455 (0.8) | 238 (0.3) | <0.001 |
| SGLT2i | 14,516 (2.8) | 0 | 14,516 (20.4) | <0.001 |
| GLP-1RA | 833 (0.2) | 598 (0.1) | 235 (0.3) | <0.001 |
| Cardiovascular medications | ||||
| ACEi/ARB | 347,273 (67.0) | 296,864 (66.4) | 50,409 (70.7) | <0.001 |
| Statins | 393,010 (75.8) | 330,815 (74.0) | 62,195 (87.3) | <0.001 |
| ASA | 341,707 (65.9) | 289,442 (64.7) | 52,265 (73.4) | <0.001 |
Values are presented as mean±standard deviation, number (%), or median (range).
SGLT2i, sodium-glucose cotransporter 2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockade; ASA, aspirin.
a
Drug that was first prescribed and billed after hospitalization for atherosclerotic cardiovascular disease.